Behavioral Management in Dementia. a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad
|
|
|
- Osborne Booker
- 6 years ago
- Views:
Transcription
1 Behavioral Management in Dementia a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad
2 Game Plan 1. Definition 2. Epidemiology 3. Assessment: IT S OVER 4. Nonpharmacologic Strategies: 4 S 5. Nonpharmacologic: Other Therapies
3 6. Pharmacotherapy:» Anti-dementia agents» Antipsychotics» Antidepressants» Anticonvulsants» Others Game Plan 7. Closing thoughts: AAGP 8. P.S. New dementia drugs on the horizon
4 The worst wounds are those that are self-inflicted William Clinton
5 Definition Agitation inappropriate verbal, motor, or vocal activity that does not result from need. Alternately, Behavioral and Psychiatric Symptoms of Dementia (BPSD) is used for clinical simplicity in describing the constellation of difficult behaviors arising in demented patients.
6 Inappropriate Behaviors Physically aggressive behaviors (hitting, kicking, biting). Physically nonaggressive behaviors (pacing, inappropriate touching). Verbally aggressive behaviors (cursing or screaming). Verbally nonaggressive behaviors (repetitive requests or phrases).
7 Epidemiology Nursing homes now function as long-term psychiatric hospitals for the elderly Anon. Agitation common 70-90% demented NH patients; 50% become aggressive Behavioral problems of dementia do not correlate with cognitive decline (although functional changes do).
8 Epidemiology In general, behavioral disturbances peak in middle stages of dementia. Psychosis is significantly associated with aggression. Delusions present in 38-73% of AD patients with paranoid delusions the most common.
9 Epidemiology Hallucinations more visual than auditory. Depression extremely common but underdiagnosed. Difficult to diagnose; tearfulness and anorexia with weight loss remain important clues.
10 Assessment Ideally, assess in nursing home. Collateral history paramount. Insist on specifics. ALWAYS ask about sleep, appetite, and whether the patient cries or seems persistently sad. Formal rating scales exist: NPI, Cohen-Mansfield Agitation Inventory.
11 Assessment Agitation is usually multifactorial, therefore consider the ITS OVER mnemonic. I Identify What is the problem? T Timing When does it happen? S Surroundings Where does it happen? O Others Involved Who else is involved? V Very troubling How dangerous is it? E Evaluation What else might be a cause? R Response How do I/we respond?
12 Assessment ALWAYS consider:» Environment» Medical» Psychiatric» Dementia
13 Nonpharmacologic Strategies First-line 4-S mnemonic:» SAFETY: control risk-driving, financial, physical.» SERENITY: manage affect-simplify, communicate affection, distract.» STRUCTURE: regulate/organize environment, establish a routine.» SANITY: reduce caregiver burden, realistic expectations, seek social support, use respite.
14 Nonpharmacologic Strategies Validation therapy-naomi Feil Focus is on empathy; caregivers to accept the values, beliefs and reality of the person with dementia.
15 Nonpharmacologic Strategies Bright light therapy. Therapeutic touch, massage. Music, art, pet therapies. Simulated presence audiotape therapy. Multisensory stimulation (Snoezelen room installation)/ simple pleasures / recreational therapies.
16 Nonpharmacologic Use of Restraints Use as last resort on a short-term basis. Constant reevaluate. CONCERNS:» Inappropriate Application quick fix.» Morbidity and Mortality» Psychological Factors» Regulatory Agency
17 If you come to a fork in the road, take it Yogi Berra
18 Pharmacotherapy CAVEATS: When psychotropics are used:» Lowest Effective Dose (L.E.D.)» Shortest time necessary» Close monitoring» Judicious use» Constant vigilance for side effects
19 Pharmacotherapy Cholinesterase Inhibitors Cholinergic agents are downstream neuroleptics. G. Grossberg MD Anti-dementia agents: first observe impact on behavioral symptoms, as milder disturbances may not require other psychotropic drugs. Early initiation is vital. Consistent benefit in irritability and disinhibition.
20 Pharmacotherapy Memantine Different mechanism of action, NMDA receptor antagonist. Reduces noise and calcium overload. Effective as monotherapy in moderate to severe AD. Significant benefits in decreasing delusions, apathy/indifference, and irritability/lability. Combination therapy (donepezil and memantine) benefited agitation/aggression, irritability/lability, and appetite/eating changes.
21 Pharmacotherapy Antipsychotics Psychotic symptoms are common and associated with aggression in dementia. Antipsychotics are modestly effective. Conventional antipsychotics used for decades; no single standout but Haldol most commonly used. Cochrane review suggest Haldol useful for aggression but associated with increased side effects.
22 Pharmacotherapy Antipsychotics Atypical antipsychotics emerging as drug of choice for BPSD. Orally disintegrating formulations preferable. Body of data with Zyprexa and Risperdal. Seroquel with emerging benefit in Lewy body dementia and Parkinson s dementia. Clozaril reserved for PD with dementia.
23 Pharmacotherapy Antipsychotics Newest agents, Abilify and Geodon, data in elderly is accumulating. Recent warnings per FDA regarding increased risk of cardiovascular events.
24 Pharmacotherapy Antidepressants Depressive symptoms common in AD. Therefore, maintain low threshold for diagnosis. Diagnosis of depression difficult; demented patient may not recognize symptoms of depression or may be unable to articulate symptoms. Tearfulness, decreased appetite with weight loss, social withdrawal are key symptoms.
25 Pharmacotherapy Antidepressants SSRIs preferred; effective, safe, well-tolerated. Celexa/Lexapro and Zoloft have minimal-zero drug-drug interactions. Single study demonstrated Celexa outperformed antipsychotic for BPSD symptoms in nondepressed, demented patients.
26 Pharmacotherapy Antidepressants Celexa/Lexapro and Zoloft preferred SSRIs in elderly Trazadone important alternative, widely used in UK DBPC trial: Trazadone as effective as Haldol in BPSD (and better tolerated) Trazadone also helpful as PRN sedative.
27 Pharmacotherapy Antidepressants Remeron may be useful in the elderly. Earlier onset of action, fairly well-tolerated. Has appetite stimulant effect, weight gain, and sedative effect. Remeron available in rapidly dissolving formulation.
28 Pharmacotherapy Anticonvulsants When antipsychotics and antidepressants fail Many anecdotal reports suggest benefit; body of data with Depakote and Tegretol/Trileptal. Some data with Neurontin. Suggestion of neuroprotection with Depakote and Lithium. Acute, individual use generally preferred. Serum drug levels critical; Threshold for toxicity is lower in elderly.
29 Pharmacotherapy Alternatives Anxiolytics/Benzodiazepines commonly prescribed in the elderly, esp. as PRN for agitation. Avoid long acting Benzodiazepines (i.e., Valium, Tranxene, Klonopin). Concerns exist: falls, paradoxical excitement, cognitive dulling, amnestic effecs, abuse/dependency potential. A single study suggests Xanax as effective as Haldol in managing disruptive episodes.
30 Pharmacotherapy Alternatives Buspar helpful. Not addictive. IM Progesterone q 2 weeks or PO Premarin useful for hypersexuality in demented males. Provigil (wakefulness agent) may be useful for excessive sleepiness/apathy. Inderal
31 AAGP Position Paper Patients SAFETY: Falls, wandering, driving, accidents, etc. Alzheimer s Association-Safe Return. Childproof house. STRUCTURE: Simplify/organize day. Establish, then maintain routine, i.e. regular toileting. MEDICAL MANAGEMENT: Meticulous medical care; Rule-out UTI, pneumonia, fecal impation, pain, dehydration. ADVANCE DIRECTIVE: Never too early.
32 AAGP Position Paper Caregivers EDUCATE, EDUCATE, EDUCATE. PROBLEM-SOLVING: Role-play behavior. LONG-RANGE PLANNING: The 36 Hour Day by P. Rabins, MD. ACCESS RESOURCES EMOTIONAL SUPPORT RESPITE, RESPITE, RESPITE.
33 P.S. New Approaches A beta modulation, inhibition, immunization. Oxidative Stress Inflamation
34 New Approaches Abeta modulation-secretase modulators Abeta inhibition of aggregation:» ALZHEMD Abeta immunization: active vaccine Abeta immunization: passive vaccine IVIG
35 New Approaches Oxidative Stress: Vitamin E modifications max dose 400 IU/d. Oxidative Stress: Curcurim?
36 New Approaches Reduce inflammation: r-fluriprofen, a nontoxic antiinflammatory with the potential to decrease production of Abeta.
37 Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less. Marie Curie
38
39 Thank you!
40
41
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
Recognition and Management of Behavioral Disturbances in Dementia
Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic
BEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
Medication Treatment of Cognitive and Behavioral Symptoms in Dementia
Medication Treatment of Cognitive and Behavioral Symptoms in Dementia Cary J. Kohlenberg, M.D. Medical Director, IPC Research and Independent Psychiatric Consultants Environmental interventions directly
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
Psychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
Addressing Difficult Behaviors in Dementia
Addressing Difficult Behaviors in Dementia GEORGE SCHOEPHOERSTER, MD GERIATRICIAN GENEVIVE/CENTRACARE CLINIC Objectives By the end of the session, you will be able to: 1) Explain the role of pain management
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
Management of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
Management of Behavioral Symptoms in Dementia. Brenda Jordan, MS, ARNP, BC- PCM Dartmouth-Hitchcock Kendal
Management of Behavioral Symptoms in Dementia Brenda Jordan, MS, ARNP, BC- PCM Dartmouth-Hitchcock Kendal Behavioral Symptoms Common & troubling At least one will occur in 61-92% of those with any dementia
Behavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
Reality, as perceived by the patient, constitutes the reality of the situation. My Mother s Doing What???!!
My Mother s Doing What???!! Management & Treatment of Dementia Related Behaviors Objectives Describe the prevalence, etiology of dementia related behaviors that include physical outbursts & sexual hyperactivity.
Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults
Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Cherie Simpson, PhD, APRN, CNS-BC Myth vs Fact All old people get depressed. Depression in late life is more enduring and
The Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school
The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence
HDSA welcomes you to Caregiver s Corner. Funded by an educational grant from
HDSA welcomes you to Caregiver s Corner Funded by an educational grant from Caregiver s Corner Webinar, DATE Managing Psychiatric Symptoms Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics
Management of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
Neuropsychiatric Syndromes
Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use
Creating Partnerships. Laine Young-Walker, MD
Creating Partnerships Laine Young-Walker, MD Psychiatry is the medical specialty devoted to the study, diagnosis, treatment and prevention of mental disorders. Medical school >>>four years of residency
THE BEHAVIOURAL VITAL SIGNS (BVS) TOOL
DID YOU KNOW THE BEHAVIOURAL VITAL SIGNS (BVS) TOOL. Did you know that it is essential to know the target cluster(s)/symptom(s) one is treating to guide and monitor non-pharmacological approaches and pharmacological
Non-pharmacological Approaches in Dementia Care. Dr. Anna Fisher
Non-pharmacological Approaches in Dementia Care Dr. Anna Fisher What is Dementia Dementia is a group of symptoms that may accompany certain diseases or conditions Symptoms many involve changes in personality,
Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment
Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
Introduction to Dementia: Complications
Introduction to Dementia: Complications Created in March 2005 Duration: about 15 minutes Axel Juan, MD The Geriatrics Institute axel.juan@med.va.gov 305-575-3388 Credits Principal medical contributor:
Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
40% of mild cognitive impairment 60% of patients in early stage of dementia
BPSD Vague and under-researched although described clearly by Alois Alzheimer Term ratified by 1996 IPA consensus conference Not fully recognised in current diagnostic systems Bypassed by dementia strategy
DEPRESSION. Men and women of all ages, races, and economic levels can have depression. It occurs more often in women.
DEPRESSION The exact cause of depression is not known. Many researchers believe it is caused by chemical imbalances in the brain, which may be hereditary or caused by events in a person's life. Some types
The place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP
Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia
Pharmacologic Management of Mood and Behavioral Changes in
Pharmacologic Management of Mood and Behavioral Changes in Dementia James E. Galvin, MD, MPH Professor of Neurology and Psychiatry New York University Langone Medical Center CADASIL MRI scan showing leukoencephalopathyon
Psychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
Managing Challenging Behaviors
Managing Challenging Behaviors Barbara J. Kocsis, MD Psychiatry Resident, HDSA Center of Excellence UC Davis School of Medicine & Lorin M. Scher, MD Attending Psychiatrist, HDSA Center of Excellence UC
Managing Challenging Behaviors
Managing Challenging Behaviors Barbara J. Kocsis, MD Psychiatry Resident, HDSA Center of Excellence UC Davis School of Medicine In partnership with Drs. Lorin Scher, MD and Vicki Wheelock, MD 1 Our Goal
Pharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
DEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
Amanda Adams-Fryatt RN MN Nurse Practitioner WRHA
Amanda Adams-Fryatt RN MN Nurse Practitioner WRHA Discuss the prevalence of BPSD Discuss the etiology of Disruptive Vocalizing Discuss memory and communication Discuss the Needs-Based Models Discuss the
Drugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
Antipsychotics for Dementia Under Control or Over-Prescribed?
Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most
Vanderbilt & Qsource Webinar Series
Vanderbilt & Qsource Webinar Series Vanderbilt Medical Center Vanderbilt University Center for Quality Aging Qsource Session #1: Introduction to Dementia Care & QAPI Session #2: Dementia & Behavioral Disturbances
Delirium. Geriatric Giants Lecture Series Divisions of Geriatric Medicine and Care of the Elderly University of Alberta
Delirium Geriatric Giants Lecture Series Divisions of Geriatric Medicine and Care of the Elderly University of Alberta Overview A. Delirium - the nature of the beast B. Significance of delirium C. An approach
Difficult Behaviors: Managing without Antipsychotics
Difficult Behaviors: Managing without Antipsychotics P R O V I D E D B Y : Requirements Requirements to receive continuing education credit: Attendance at entire event Must sign in & provide email address
2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources
Drugs and Dementia in the Hospice Patient Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources 1 Drug Therapy: Targeted at Symptoms Cognitive: Impaired abstract thinking Impaired
Psychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
Behavior Problems: in Long Term Care and Assisted Living
Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module I Dr. David A. Smith, M.D., FAAFP, CMD mmlearn.org is a program of Morningside Ministries Cell Phones and Pagers
Caring for the Mind: Managing Depression and Anxiety. Highlights from 2017 ONS Congress
Caring for the Mind: Managing Depression and Anxiety Highlights from 2017 ONS Congress Mood and Anxiety Disorders: Symptoms of mood disorders Non-reactive mood, worthlessness, guilt, loss of interest,
Identifying and Assisting Lawyers and Judges with Cognitive Impairments. National Council for Lawyer Assistance Programs.
Identifying and Assisting Lawyers and Judges with Cognitive Impairments National Council for Lawyer Assistance Programs October 9, 2012 Susan Stone, JD, MD Susan Stone and Associates PO Box 220, 180 Bradley
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
Managing Behavioral Issues
2:45 3:45pm Caring for the Older Patient Handling Behavioral Issues Presenter Disclosure Information The following relationships exist related to this presentation: Samir Sabbag, MD, has no financial relationships
Psychiatric and Behavioral Challenges in HD
Psychiatric and Behavioral Challenges in HD Lorin M. Scher, MD Department of Psychiatry and Behavioral Sciences UC Davis School of Medicine June 8 th 2012 1 Disclosure Advisory Board for Lundbeck Inc.
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
9/11/2012. Clare I. Hays, MD, CMD
Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management
Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
Multi-morbidity in Dementia: A 21st Century Challenge. Sube Banerjee. Professor of Dementia Brighton and Sussex Medical School
Multi-morbidity in Dementia: A 21st Century Challenge Sube Banerjee Professor of Dementia Brighton and Sussex Medical School Most people of any age with any long term condition have multiple conditions
Managing agitation in dementia using non-pharmacological therapies
Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia
This information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.
Supporting people with dementia and their carers Information for the public Published: 1 November 2006 nice.org.uk About this information NICEclinicalguidelinesadvisetheNHSoncaringforpeoplewithspe cificconditionsordiseasesandthetreatmentstheyshouldreceive.
Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
Treatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
How Aging and Dementia Effect Resident Behaviors
How Aging and Dementia Effect Resident Behaviors November 3, 2011 1:00 2:00 PM EST Webinar Presented by: Alfred W. Norwood, BS, MBA Education Arm of the Carmelite Sisters for the Aged and Infirm Webinar
Professor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
Understanding Dementia-Related Changes in Communication and Behavior
Understanding Dementia-Related Changes in Communication and Behavior Objectives for this workshop To better understand Dementia (Alzheimer s disease) To learn the principles and practical techniques in
Antipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
Parkinsonian Disorders with Dementia
Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University
Delirium. Delirium. Delirium Etiology and Pathophysiology. Fall 2018
Three most common cognitive problems in adults 1. (acute confusion) 2. Dementia 3. Depression These problems often occur together Can you think of common stimuli for each? 1 1 State of temporary but acute
Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
Understanding Dementia
Understanding Dementia Behaviors Kim P. Petersen MD Spring Green, WI Why Persons with Dementia Do What They Do Environmental Triggers Relocation Architectural maze Uncomfortable environment: (too hot/
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.
ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue
Study Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia
Dementia Training Session for Carers. By Dr Rahul Tomar Consultant Psychiatrist
Dementia Training Session for Carers By Dr Rahul Tomar Consultant Psychiatrist Dementia in the UK: Facts & Figures National Dementia strategy launched in 2009 800,000 people living with dementia (2012)
National Task Group Early Detection Screen for Dementia (NTG-EDSD) Lucy Esralew, Ph.D. Chair, Screening NTG/AADMD
National Task Group Early Detection Screen for Dementia (NTG-EDSD) Lucy Esralew, Ph.D. Chair, Screening NTG/AADMD Why develop an Administrative Tool? Need to capture observation of change early enough
Delirium. Delirium is characterized by an acute onset (hours or days) and fluctuating course of deterioration in mental functioning.
Delirium Delirium is characterized by an acute onset (hours or days) and fluctuating course of deterioration in mental functioning. DELIRIUM IS A MEDICAL EMERGENCY! Delirium: Hallmark Features Inattention-
Medications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
Greg Jicha, M.D., Ph.D. Associate Professor of Neurology The Robert T. & Nyles Y. McCowan Chair in Alzheimer s Research University of Kentucky
Greg Jicha, M.D., Ph.D. Associate Professor of Neurology The Robert T. & Nyles Y. McCowan Chair in Alzheimer s Research University of Kentucky Alzheimer s Disease Center and the Sanders-Brown Center on
Risks of Antipsychotics use In Dementia
AHCA/NCAL Quality Initiative for Assisted Living Webinar Series: Safely Reducing the Off-Label Use of Antipsychotics Risks of Antipsychotics use In Dementia Sanjay P. Singh, MD Chairman & Professor, Department
Across the Spectrum of Dementia. Keys to Understanding Behaviours & Anticipating Needs
Across the Spectrum of Dementia Keys to Understanding Behaviours & Anticipating Needs Outline Review current predictions for dementia prevalence, & the implications for future needs Discuss retrogenesis
Seniors Health Strategic Clinical Network Restraint as a Last Resort
Seniors Health Strategic Clinical Network Restraint as a Last Resort Elder Friendly Care 2018 Alberta Health Services, Seniors Health Strategic Clinical Network Disclaimer, Copyright and Creative Commons
GENI Jeopardy: Geriatric Mental Health. Part of the brain responsible for executive functioning
GENI Jeopardy: Geriatric Mental Health Part of the brain responsible for executive functioning Dementia: It is not just forgetfulness GENI February 20, 2008 Marcia Carr - CNS Dementia Dementia means brain
Mental Health Issues in Nursing Homes. I m glad you asked.
Mental Health Issues in Nursing Homes I m glad you asked. I m glad you asked Susan Wehry, M.D. Associate Professor of Psychiatry, College of Medicine, University of Vermont Consultant, State of Vermont
Delirium and Care Giving
Delirium and Care Giving Marianne McCarthy, PhD, RN Advanced Practice Nurse Sun Health Geriatric Fellowship Program Associate Professor Arizona State University Presentation Questions What happens when
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral
Restrained use of antipsychotic medications:
Balanced information for better care Restrained use of antipsychotic medications: Rational management of irrationality These drugs are commonly prescribed in conditions for which there is little evidence
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
An Overview on the Use of Psychotropic Medications
An Overview on the Use of Psychotropic Medications Marilyn B. Benoit, M.D. Chief Clinical Officer SVP, Clinical & Professional Affairs Classes of Medications Antidepressants Anti-anxiety Mood stabilizers
Class: Treatment with Medication:
Class: As we have not finished all the material covering disorders, I wanted to give you and overview of some disorders we have not had a chance to discuss. I feel you are well prepared in different types
Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
Presenter Disclosure Information 3:45 4:45pm The following relationships exist related to this presentation: Strategies for Optimizing
3:45 4:45pm Strategies for Optimizing Dementia Care for Patients and Caregivers SPEAKER Elizabeth Crocco, MD Presenter Disclosure Information The following relationships exist related to this presentation: